BiotechTube

levothyroxine sodium

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypothyroidism

Conditions

Hypothyroidism

Trial Timeline

May 15, 2023 → Feb 22, 2024

NCT ID
NCT05823012

About levothyroxine sodium

levothyroxine sodium is a phase 2 stage product being developed by Xeris Pharmaceuticals for Hypothyroidism. The current trial status is completed. This product is registered under clinical trial identifier NCT05823012. Target conditions include Hypothyroidism.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05823012Phase 2Completed

Competing Products

5 competing products in Hypothyroidism

See all competitors
ProductCompanyStageHype Score
Growth hormone + Growth hormone treatment and pubertyEli LillyApproved
85
Armour Thyroid + LevothyroxineAbbViePhase 2/3
65
iodinated contrast agentsBayerPre-clinical
20
Iohexol + Iodixanol + Iopromide + IoversolBayerApproved
82
Iodinated contrast agentsBayerPre-clinical
20

Other Products from Xeris Pharmaceuticals

G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])Phase 3
72
G-Pen + Novo GlucagonPhase 3
72
G-Pen + Lilly GlucagonPhase 3
72
GlucagonPhase 3
72
Glucagon RTUPhase 2
47